Shares of TrovaGene Inc. surged more than 20% on Friday on news that the company’s urine-based Precision Cancer Monitoring, or PCM, platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients.